A comparative observational study of patients with atrophic gastritis to examine the standard values of serum gastrin and pepsinogen related to diagnostic criteria for autoimmune gastritis

A comparative observational study of patients with atrophic gastritis to examine the standard values of serum gastrin and pepsinogen I, II, I/II ratio related to diagnostic criteria for autoimmune gastritis - Comparative observation study on diagnostic criteria for autoimmune gastritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040053

Enrollment

360

Registered

2020-04-04

Start date

2020-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrophic gastritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: EGD between April 1 2011 and April 30 2020, with atrophic gastritis, for which gastrin or PG was measured as clinical necessity or as a screening item. The registration period will be November 30, 2020 from the approval date of each facility ethics committee. They are classified and registered in the following a)-f). a) AIG group (pathologically matched + autoantibody positive) group: Pathological diagnostic criteria in the attached draft 3) Satisfies # 1 or # 1 + # 2 and is positive for PCA or IFA b) AIG group (pathology unknown + autoantibody positive) group: no histological examination or pathological criteria not evaluated, and PCA or IFA is positive. c) Non-AIG (pathological non-AIG + autoantibody negative) group: Hp gastritis (Hp eradication) that does not satisfy the attached draft pathological diagnostic criteria # 1 or # 2 and is PCA (-) and IFA (-) (including Hp eradicate successful examples) d) Non-AIG (pathological unknown + autoantibody negative) group: Hp gastritis (including successful cases of Hp eradication) for which no histological examination or pathological criteria have been evaluated, and which is PCA (-) and IFA (-). e) Non-AIG (pathological non-AIG + PCA (-) group: Hp gastritis that does not meet the attached draft pathological diagnostic criteria # 1 or # 2 and is PCA negative (including successful Hp eradication). f) Non-AIG (pathologic non-AIG + PCA (-) group: Endoscopic atrophic gastritis (Hp infection history Is not clear).

Exclusion criteria

Exclusion criteria: After gastrectomy, taking proton pump inhibitor (PPI) or vonoprazan fumarate, renal failure

Design outcomes

Primary

Measure	Time frame
Gastrin values, PG I, II, I / II values for AIG and non-AIG cases	—

Countries

Japan

Contacts

Public ContactTOMOARI KAMADA

Kawasaki Medical School Dept. of Health Care Medicine

tkamada@med.kawasaki-m.ac.jp086-225-2111

Outcome results